Skip to main
LQDA

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 13%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Liquidia is a biopharmaceutical company focused on developing, manufacturing, and commercializing products to treat pulmonary hypertension (PH) and related conditions using its proprietary PRINT technology. This technology allows for precise production of uniform drug particles, making Liquidia's products effective and appealing to patients. The company has seen impressive sales growth for its lead product, Yutrepia, and has a strong pipeline, with potential for expanded indications and new product launches. While there may be some competition in the market, Liquidia's products and technology position it for continued success and potential future growth.

Bears say

Liquidia is facing significant legal and competitive risks in the near future with ongoing patent disputes and potential delays in launching their lead candidate, Yutrepia, for the treatment of pulmonary hypertension. With potential disruptions in sales and no definite timeline for resolution, the company may struggle to achieve peak commercial revenue. Additionally, competition from other companies in the market may also impede their success. Despite a positive outlook from KOL sentiment and increased market penetration, these factors significantly increase the risk surrounding Liquidia's stock.

LQDA has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 13% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 8 analysts, LQDA has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $89.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $89.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.